There could be big money to be made based on the final results of a study to be announced at the American Society of Clinical Oncology beginning May 31. Cancer patients, doctors and pharmaceutical companies all have a lot of stake in the next wave of experimental cancer drugs, which use the human immune system to work against the disease.

Read the story.